Metraipolis › archive › dc_6fa8ef2df886

Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022-2024 Period — Europe PMC PMID:42797610

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42797610
DOI
10.3390/vaccines14090790
License (as archived)
solo-consultazione
Archived
2026-10-07T11:33:24.241Z
SHA-256 of the archived text
2a65a465e659eb76fceebaea27e53bf1acbb9c7e61b16a093843b3cef8e9f230
Stable URL of this page
https://metraipolis.com/documento/dc_6fa8ef2df886

How to cite

Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022-2024 Period — Europe PMC PMID:42797610 — Europe PMC (en), https://europepmc.org/article/MED/42797610 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6fa8ef2df886 (Metraipolis archive dc_6fa8ef2df886, sha256 2a65a465e659eb76fceebaea27e53bf1acbb9c7e61b16a093843b3cef8e9f230)
BibTeX
@misc{dc6fa8ef2df886,
  title = {Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022-2024 Period — Europe PMC PMID:42797610},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42797610},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6fa8ef2df886; sha256 2a65a465e659eb76fceebaea27e53bf1acbb9c7e61b16a093843b3cef8e9f230},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42797610. Agents can read the archived copy with the MCP tool read_document.